Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.

Saw SPL, Low YF, Lai GGY, Chan LL, Wong WKY, Tsui G, Chen OH, Seet AOL, Tan WC, Tan AC, Chan JWK, Teh YL, Tan WL, Ng QS, Ang MK, Kanesvaran R, Lim DWT, Tan DSW, Mok TSK, Li MSC

Open source

DOI: 10.1016/j.lungcan.2024.107856
Published: 2024 Jul
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2024.107856,
  title = {Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.},
  author = {Saw SPL and Low YF and Lai GGY and Chan LL and Wong WKY and Tsui G and Chen OH and Seet AOL and Tan WC and Tan AC and Chan JWK and Teh YL and Tan WL and Ng QS and Ang MK and Kanesvaran R and Lim DWT and Tan DSW and Mok TSK and Li MSC},
  year = {2024},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2024.107856},
  url = {https://doi.org/10.1016/j.lungcan.2024.107856}
}

RIS

TY  - JOUR
TI  - Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
AU  - Saw SPL
AU  - Low YF
AU  - Lai GGY
AU  - Chan LL
AU  - Wong WKY
AU  - Tsui G
AU  - Chen OH
AU  - Seet AOL
AU  - Tan WC
AU  - Tan AC
AU  - Chan JWK
AU  - Teh YL
AU  - Tan WL
AU  - Ng QS
AU  - Ang MK
AU  - Kanesvaran R
AU  - Lim DWT
AU  - Tan DSW
AU  - Mok TSK
AU  - Li MSC
PY  - 2024
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2024.107856
UR  - https://doi.org/10.1016/j.lungcan.2024.107856
ER  -

APA

SPL, S., YF, L., GGY, L., LL, C., WKY, W., G, T., OH, C., AOL, S., WC, T., AC, T., JWK, C., YL, T., WL, T., QS, N., MK, A., R, K., DWT, L., DSW, T., TSK, M., & MSC, L. (2024). Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2024.107856

Source records

pubmed · retrieved 2026-09-26T17:12:53.214Z
europe-pmc · retrieved 2026-09-26T17:12:53.215Z